CELLURIS

 

Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting it accurately.

This way, revolutionizing cancer treatment through an innovative immunotherapy approach is the purpose of Celluris. We are the Brazilian reference company in cell therapy treatments to fight cancer. To meet such a relevant challenge, we used Chimeric Antigen Receptor T-cells Therapy (CAR-T), currently available in the United States, European Union countries and Israel. In Brazil, it was regulated by the National Health Agency (Anvisa) in February 2020.

This therapeutic alternative has shown impressive results in clinical tests in several countries during the treatment of patients affected by hematological and solid tumors. In Brazil, we are the first company dedicated to this field.

This technology is still being tested in Brazil, but we are already on the way to make the therapy accessible and ready to be applied following the highest standards of bioethics. Our team of experts has leading names like P.h.D. Martin Bonamino and Dr. Sergio Simon, who work as members of the Scientific Committee.

Located in São Paulo, Brazil, Celluris was founded in 2016 by Yechiel Stern, co-founder of Atvio, an Israeli company specialized in the development of processes and products in the field of biotechnology, and partner at Masthercell, an important CDMO in the industry. Since then, we have won the support and partnership of different organizations in countries like Brazil, the United States, Israel and Switzerland.